奥拉帕尼
叙述的
药品
医学
药理学
艺术
文学类
生物
生物化学
聚合酶
基因
聚ADP核糖聚合酶
作者
Vivekanand Sharma,Aparna Sharma
标识
DOI:10.4103/crst.crst_107_21
摘要
Olaparib is an oral anticancer drug that inhibits the poly adenosine diphosphate-ribose polymerase protein (PARP). It is approved for use in advanced ovarian, breast, pancreatic, and prostate cancers. For this review, we comprehensively searched the PubMed database and Google for randomized trials and meta-analyses using the keywords “breast cancer,” “pancreatic cancer,” “ovarian cancer,” “prostate cancer,” and “olaparib.” A total of 78 randomized studies, meta-analyses, and other studies were identified, of which 70 were finally included. In this review, we have attempted to elucidate the history, pharmacokinetics, pharmacodynamics, adverse event profile, and special scenarios nvolving the use of olaparib. In addition, we have briefly reviewed the existing literature for its use in ovarian, pancreatic, breast, and prostate cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI